| 000 | 01728 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250513130059.0 | ||
| 264 | 0 | _c19971124 | |
| 008 | 199711s 0 0 eng d | ||
| 022 | _a0022-5347 | ||
| 024 | 7 |
_a10.1016/s0022-5347(01)64118-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMulhall, J P | |
| 245 | 0 | 0 |
_aIntracavernosal forskolin: role in management of vasculogenic impotence resistant to standard 3-agent pharmacotherapy. _h[electronic resource] |
| 260 |
_bThe Journal of urology _cNov 1997 |
||
| 300 |
_a1752-8; discussion 1758-9 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S. | ||
| 650 | 0 | 4 |
_aAlprostadil _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 | _aCells, Cultured |
| 650 | 0 | 4 |
_aColforsin _xadministration & dosage |
| 650 | 0 | 4 |
_aCyclic AMP _xbiosynthesis |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDrug Resistance |
| 650 | 0 | 4 | _aDrug Therapy, Combination |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImpotence, Vasculogenic _xdrug therapy |
| 650 | 0 | 4 | _aInjections |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aPapaverine _xadministration & dosage |
| 650 | 0 | 4 | _aPenis |
| 650 | 0 | 4 |
_aPhentolamine _xadministration & dosage |
| 650 | 0 | 4 | _aRabbits |
| 650 | 0 | 4 |
_aVasodilator Agents _xadministration & dosage |
| 700 | 1 | _aDaller, M | |
| 700 | 1 | _aTraish, A M | |
| 700 | 1 | _aGupta, S | |
| 700 | 1 | _aPark, K | |
| 700 | 1 | _aSalimpour, P | |
| 700 | 1 | _aPayton, T R | |
| 700 | 1 | _aKrane, R J | |
| 700 | 1 | _aGoldstein, I | |
| 773 | 0 |
_tThe Journal of urology _gvol. 158 _gno. 5 _gp. 1752-8; discussion 1758-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/s0022-5347(01)64118-1 _zAvailable from publisher's website |
| 999 |
_c9307035 _d9307035 |
||